Merck Mayo AI Partnership Aims To Sharpen Drug Discovery Decisions
Merck (NYSE:MRK) and Mayo Clinic announced a new research and development partnership focused on using artificial intelligence and multimodal clinical data for drug discovery and development. The collaboration combines Mayo Clinic's large clinical and genomic datasets with Merck's AI driven virtual cell technologies to support earlier stage drug research. Mayo Clinic characterized this as its largest collaboration w…
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
